Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.
作者信息
Merry S, Flanigan P, Schlick E, Freshney R I, Kaye S B
机构信息
CRC Department of Medical Oncology, University of Glasgow, UK.
出版信息
Br J Cancer. 1989 Jun;59(6):895-7. doi: 10.1038/bjc.1989.189.
Abstract
摘要
相似文献
1
Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.一种小鼠肿瘤细胞系的内在阿霉素耐药性：用维拉帕米和去甲维拉帕米克服
Br J Cancer. 1989 Jun;59(6):895-7. doi: 10.1038/bjc.1989.189.
2
Importance of clinical exposure on verapamil enhancement of adriamycin-vincristine cytotoxicity in human neuroblastoma.临床暴露对维拉帕米增强阿霉素-长春新碱对人神经母细胞瘤细胞毒性的重要性。
Cancer Drug Deliv. 1984 Fall;1(4):303-5. doi: 10.1089/cdd.1984.1.303.
3
Verapamil potentiation of doxorubicin resistance development in B16 melanoma cells both in vitro and in vivo.维拉帕米在体外和体内均增强B16黑色素瘤细胞对阿霉素耐药性的发展。
Br J Cancer. 1988 Apr;57(4):343-7. doi: 10.1038/bjc.1988.79.
4
Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study.维拉帕米逆转人类癌症中临床多柔比星耐药性。威尔希尔肿瘤医学集团I-II期试验性研究。
Am J Clin Oncol. 1986 Aug;9(4):355-7. doi: 10.1097/00000421-198608000-00016.
5
Doxorubicin resistance circumvention by verapamil in B16 melanoma cells.维拉帕米对B16黑色素瘤细胞阿霉素耐药性的逆转作用
Anticancer Res. 1989 Jan-Feb;9(1):29-32.
6
Effects of Dex-Verapamil on Doxorubicin cytotoxicity in P388 murine leukemia cells.右美维拉帕米对P388小鼠白血病细胞中阿霉素细胞毒性的影响。
Anticancer Drug Des. 1997 Jun;12(4):261-76.
7
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.多发性骨髓瘤和非霍奇金淋巴瘤中的耐药性：P-糖蛋白的检测以及通过在化疗中添加维拉帕米来潜在规避耐药性
J Clin Oncol. 1989 Apr;7(4):415-24. doi: 10.1200/JCO.1989.7.4.415.
8
Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A.通过维拉帕米和环孢素A联合治疗提高体内耐药淋巴瘤细胞中阿霉素的细胞内浓度。
Eur J Haematol. 1994 May;52(5):276-82. doi: 10.1111/j.1600-0609.1994.tb00096.x.
9
10
Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil.人胶质瘤对阿霉素的体外耐药性：膜转运的作用及维拉帕米对其的规避作用
Br J Cancer. 1986 Jan;53(1):129-35. doi: 10.1038/bjc.1986.18.
引用本文的文献
1
Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer.右维拉帕米与表柔比星治疗转移性乳腺癌无效患者的II期试验
Br J Cancer. 1998 Apr;77(7):1155-63. doi: 10.1038/bjc.1998.192.
2
Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.右维拉帕米调节转移性肾细胞癌对长春碱的耐药性。
J Cancer Res Clin Oncol. 1995;121 Suppl 3(Suppl 3):R11-6. doi: 10.1007/BF02351065.
3
A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.维拉帕米联合化疗用于小细胞肺癌的随机临床研究。苏格兰西部肺癌研究组及阿伯丁肿瘤学组。
Br J Cancer. 1993 Oct;68(4):813-8. doi: 10.1038/bjc.1993.433.
4
R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.R-维拉帕米：药代动力学及其对PR间期、血压和心率的影响
Br J Clin Pharmacol. 1993 Aug;36(2):93-8. doi: 10.1111/j.1365-2125.1993.tb04202.x.
5
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.口服维拉帕米联合化疗治疗晚期非小细胞肺癌：一项随机研究。
Br J Cancer. 1993 May;67(5):1031-5. doi: 10.1038/bjc.1993.189.
6
Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.表柔比星与多药耐药逆转剂D-维拉帕米之间的药代动力学相互作用。
Br J Cancer. 1993 Jul;68(1):8-9. doi: 10.1038/bjc.1993.277.
7
Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers.持续输注维拉帕米联合依托泊苷治疗复发或难治性儿童癌症。
Br J Cancer. 1995 Apr;71(4):877-81. doi: 10.1038/bjc.1995.169.
8
Biochemical and ultrastructural studies on the effect of verapamil on formation and secretion of lipoproteins in rat hepatocyte suspensions.维拉帕米对大鼠肝细胞悬液中脂蛋白形成和分泌影响的生化及超微结构研究。
Arch Toxicol. 1990;64(8):656-62. doi: 10.1007/BF01974694.
9
Verapamil and hematoporphyrin derivative for tumour destruction by photodynamic therapy.维拉帕米与血卟啉衍生物用于光动力疗法破坏肿瘤
Br J Cancer. 1991 Jul;64(1):84-6. doi: 10.1038/bjc.1991.244.
10
A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.一项关于体内多药耐药性（MDR）逆转的I期研究：硝苯地平加依托泊苷。
Br J Cancer. 1992 Feb;65(2):267-70. doi: 10.1038/bjc.1992.53.
本文引用的文献
1
The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog.维拉帕米的药理学。V. 维拉帕米和去甲维拉帕米在大鼠和犬体内的组织分布。
Pharmacology. 1983;27(1):1-8. doi: 10.1159/000137823.
2
Cross-resistance to cytotoxic drugs in human glioma cell lines in culture.培养的人胶质瘤细胞系对细胞毒性药物的交叉耐药性。
Br J Cancer. 1984 Dec;50(6):831-5. doi: 10.1038/bjc.1984.263.
3
Verapamil restoration of daunorubicin responsiveness in daunorubicin-resistant Ehrlich ascites carcinoma.维拉帕米恢复多柔比星对多柔比星耐药艾氏腹水癌的反应性
J Clin Invest. 1982 Nov;70(5):1131-4. doi: 10.1172/jci110702.
4
Phase I study of vinblastine and verapamil given by concurrent iv infusion.长春碱与维拉帕米同步静脉输注的I期研究。
Cancer Treat Rep. 1985 Jul-Aug;69(7-8):795-9.
5
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.基于四氮唑的半自动比色法评估：化学敏感性测试评估
Cancer Res. 1987 Feb 15;47(4):936-42.
6
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.维拉帕米与阿霉素治疗耐药性卵巢癌患者
J Clin Oncol. 1987 Apr;5(4):641-7. doi: 10.1200/JCO.1987.5.4.641.
7
Tumour cell resistance to anthracyclines--a review.
Cancer Chemother Pharmacol. 1985;14(2):96-103. doi: 10.1007/BF00434344.
8
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.低剂量氨鲁米特联合与不联合氢化可的松对绝经后乳腺癌患者内分泌影响的比较。
Br J Cancer. 1985 Oct;52(4):525-9. doi: 10.1038/bjc.1985.223.
9
Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.
Cardiovasc Res. 1978 Apr;12(4):247-54. doi: 10.1093/cvr/12.4.247.
Zotero 插件